Effectiveness of Ticagrelor Compared to Clopidogrel in Reducing the Risk of Major Adverse Cardiovascular Events in Patients with Coronary Heart Disease After Percutaneous Coronary Intervention

被引：0
|
作者：
Nur'amin, Hendra Wana [1 ]
Dwiprahasto, Iwan [2 ]
Kristin, Erna [2 ]
机构：
[1] Lambung Mangkurat Univ, Pharmacol & Therapy, Banjarmasin, South Kalimanta, Indonesia
[2] Gadjah Mada Univ, Pharmacol & Therapy, Yogyakarta, Indonesia
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2016年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
975
引用
收藏
页码：567 / 567
页数：1
相关论文
共 50 条
  • [1] Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
    Turgeon, Ricky D.
    Koshman, Sheri L.
    Youngson, Erik
    Har, Bryan
    Wilton, Stephen B.
    James, Matthew T.
    Graham, Michelle M.
    JAMA INTERNAL MEDICINE, 2020, 180 (03) : 420 - 428
  • [2] Association of ticagrelor versus clopidogrel with major adverse cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention across categories of liver disease
    Hong, Bin
    Bea, Sungho
    Shin, Ju-Young
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 153 - 154
  • [3] The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention
    Zhang, Zhaowei
    Chen, Mingxiao
    Zhang, Long
    Zhao, Qiang
    BMC PHARMACOLOGY & TOXICOLOGY, 2020, 21 (01):
  • [4] The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention
    Zhaowei Zhang
    Mingxiao Chen
    Long Zhang
    Qiang Zhao
    BMC Pharmacology and Toxicology, 21
  • [5] The Personality and Psychological Stress Predict Major Adverse Cardiovascular Events in Patients With Coronary Heart Disease After Percutaneous Coronary Intervention for Five Years
    Du, Jinling
    Zhang, Danyang
    Yin, Yue
    Zhang, Xiaofei
    Li, Jifu
    Liu, Dexiang
    Pan, Fang
    Chen, Wenqiang
    MEDICINE, 2016, 95 (15)
  • [6] Proton Pump Inhibitor and Clopidogrel Use After Percutaneous Coronary Intervention and Risk of Major Cardiovascular Events
    Maret-Ouda, John
    Santoni, Giola
    Xie, Shaohua
    Rosengren, Annika
    Lagergren, Jesper
    CARDIOVASCULAR DRUGS AND THERAPY, 2022, 36 (06) : 1121 - 1128
  • [7] Proton Pump Inhibitor and Clopidogrel Use After Percutaneous Coronary Intervention and Risk of Major Cardiovascular Events
    John Maret-Ouda
    Giola Santoni
    Shaohua Xie
    Annika Rosengren
    Jesper Lagergren
    Cardiovascular Drugs and Therapy, 2022, 36 : 1121 - 1128
  • [8] TRIPLE THERAPY WITH PRASUGREL OR TICAGRELOR COMPARED TO CLOPIDOGREL AFTER PERCUTANEOUS CORONARY INTERVENTION
    Coons, James
    Verlinden, Nathan
    Iasella, Carlo
    Saul, Melissa
    Kane-Gill, Sandra
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 196 - 196
  • [9] Ticagrelor as Compared to Clopidogrel Following Percutaneous Coronary Intervention for Acute
    Wiens, Evan J.
    Leon, Silvia J.
    Whitlock, Reid
    Tangri, Navdeep
    Shah, Ashish H.
    AMERICAN JOURNAL OF CARDIOLOGY, 2023, 198 : 26 - 32
  • [10] Association of lipoprotein(a) and major adverse cardiovascular events in patients with percutaneous coronary intervention
    Chen, Zhihao
    Jiang, Chaohui
    Qu, Huimin
    Liang, Shuang
    Yang, Jian
    Wu, Hui
    He, Chao
    Wang, Xinan
    ARCHIVES OF MEDICAL SCIENCE, 2019, 15 (06) : 1375 - 1380
12345